Key result
Low-dose aspirin remains the life-saving cornerstone of antithrombotic therapy across ~50 years of research.
Why the study?
The author provides a personal testimony of how 50 years of clinical research characterized low-dose aspirin as a cornerstone antithrombotic therapy.
Provides a historical perspective on the 50-year development of low-dose aspirin as a cornerstone antiplatelet therapy.
Answers are grounded in this paper and cite their sources.
Endorses low-dose aspirin as enduring standard therapy; leaves open optimization questions for contemporary comparative trials.
biosynthesis as a tool to investigate the clinical pharmacology of cyclooxygenase inhibition by aspirin in health and disease. What followed was a long, winding road of clinical research leading to the characterization of low-dose aspirin as a life-saving antiplatelet drug that still represents the cornerstone of antithrombotic therapy. Having witnessed and participated in these 50 years of aspirin research, I thought of providing a personal testimony of how things developed and eventually led to a remarkable success story of independent research.
No takes yet. Share an insight, caveat, or question.
Carlo Patrono (2022) reported a review. aspirin was evaluated. Low-dose aspirin has been established over 50 years of clinical research as a life-saving antiplatelet drug and the cornerstone of antithrombotic therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: